Microba Life Sciences (FRA:F3Y) Moat Score: 0/10 (As of Jul. 09, 2026)


FRA:F3Y Microba Life Sciences Ltd FRA:F3Y
29 GF Score
Price €0.02
GF Value €0.12
! 6 Warning Signs
View Full Analysis

What is Microba Life Sciences Moat Score?

Microba Life Sciences has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Microba Life Sciences has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Microba Life Sciences might have No Moat - No discernible moat.

Microba Life Sciences  (FRA:F3Y) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Microba Life Sciences Moat Score Related Terms

FRA:F3Y
29GF Score
Microba Life Sciences Ltd FRA:F3Y
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?

Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued. The current stock price of €0.02 is trading 85.4% below its estimated GF Value™ of €0.12.

Key valuation signals for FRA:F3Y:

  • Moat Score: 0
  • GF Value™: €0.12 vs. price of €0.02 (85.4% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microba Life Sciences Business Description

Other Exchanges MAP:Australia
Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score

Get the complete analysis for FRA:F3Y

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.12
GF Value